INTRODUCTION
============

Alveolar ridge deficiency following tooth loss compromises oral rehabilitation with implants \[[@B1]\]. Horizontal alveolar ridge augmentation (HARA) prior to implant placement is frequently necessary when dimensions of the alveolar process are inadequate \[[@B2]\].

Autogenous bone block is considered the preferred treatment modality for HARA with high survival rates of suprastructures and implants \[[@B5]\]. However, use of autogenous bone block is associated with risk of donor site morbidity, unpredictable graft resorption and possibility of injury to vital structures \[[@B11]\]. Allogeneic bone block has been proposed as an alternative in HARA to diminish morbidity and simplify the surgical procedure.

Allogeneic bone graft material derived from genetically non-identical donor of the same species is available as blocks (cortical, cancellous) or as chips or granules (cortical, cancellous). The most commonly used allogeneic bone graft materials are freeze-dried bone allograft (FDA), demineralized freeze-dried bone allograft (DFDA), and fresh-frozen bone allograft (FFA). Systematic reviews and meta-analyses have concluded that allogeneic bone graft is a suitable grafting material \[[@B14],[@B15]\]. However, allogeneic bone graft is rarely used for HARA compared with autogenous bone graft or other bone substitutes due to risk of immunologic reactions and disease transmission.

HARA with allogeneic bone block has previously been assessed in systematic reviews and meta-analyses reporting high implant survival rates and gain in alveolar ridge width \[[@B16],[@B17]\]. A recent systematic review concluded insufficient evidence is available to establish treatment efficacy relative to graft incorporation, alveolar ridge augmentation, and long-term implant survival after HARA with allogeneic bone block \[[@B18]\]. Moreover, a radiographic and histomorphometric study assessing HARA with allogeneic bone block disclosed statistically significant less vital bone and more graft resorption compared with autogenous bone block graft after 6 - 8 months \[[@B19]\], in accordance with other publications revealing significant more resorption of the augmented area, low rate of graft remodelling and clear signs of inflammation with allogeneic bone block \[[@B20]\]. Furthermore, HARA with allogeneic bone block revealed significantly less vital mineralized bone compared with allogeneic bone block impregnated with autologous bone marrow \[[@B24]\]. Therefore, implant treatment outcome after HARA with allogeneic bone block compared with autogenous bone block graft involving clinical, radiographic and histomorphometric outcome measures is presently unknown. The objective of the present systematic review was to test the hypothesis of no difference in implant treatment outcome after horizontal alveolar ridge augmentation with allogeneic bone block compared with autogenous bone block.

MATERIAL AND METHODS
====================

**Protocol and registration**

Review was conducted in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement for reporting systematic reviews \[[@B25]\]. Methods of the analysis and inclusion criteria were specified in advance and documented in a protocol and registered in PROSPERO, an international prospective register of systematic reviews.

Registration number: CRD42019129754.

The protocol can be accessed at:

<https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42019129754>.

**Focus question**

Focus question was developed according to the Patient, Intervention, Comparison and Outcome (PICO) framework as described in [Table 1](#T1){ref-type="table"}.

###### 

PICOS guidelines

  ------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Patient and population (P)**        Healthy patients with a horizontal alveolar deficiency following tooth loss or congenitally missing tooth/teeth.
                                        
  **Intervention (I)**                  Horizontal alveolar ridge augmentation with an allogeneic bone block graft.
                                        
  **Comparator or control group (C)**   Horizontal alveolar ridge augmentation with autogenous bone block graft.
                                        
  **Outcomes (O)**                      Survival of suprastructure, implant survival rate, implant stability, bone-to-implant contact, peri-implant marginal bone loss, histomorphometric assessment of new bone formation, residual allogeneic bone graft and connective tissue, gain in alveolar ridge width and volumetric reduction of the augmented area, patient-reported outcome measures, biologic and technical complications.
                                        
  **Study design (S)**                  Randomized controlled trials, controlled clinical trials, case-series and retrospective studies assessing horizontal alveolar ridge augmentation with an allogeneic bone block graft compared with autogenous bone block graft. Moreover, human studies solely assessing horizontal alveolar ridge augmentation with allogeneic bone block graft was included as non-comparative studies.
                                        
  **Focused question**                  Are there any differences in implant treatment outcome after horizontal alveolar ridge augmentation with an allogeneic bone block graft compared to autogenous bone block graft?
  ------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Eligibility criteria**

Randomized controlled trials, controlled clinical trials, case-series and retrospective human studies assessing implant treatment outcome after HARA with allogeneic bone block compared with autogenous bone block were included in this study. Human studies solely evaluating HARA with allogeneic bone block were included as non-comparative studies.

**Types of outcome measures**

-   Survival of suprastructures. Estimated by subtracting of failed suprastructures, which is defined as a complete loss of the suprastructure due to technical and/or biological complications.

-   Survival of implants. Estimated by subtracting of failed implants, which is defined as mobility of previously clinically osseointegrated implants or removal of non-mobile implants due to progressive peri-implant marginal bone loss and infection.

-   Implant stability. Estimated by magnetic resonance frequency analysis, percussion test or reverse torque test.

-   Bone-to-implant contact. Estimated by histomorphometric measurements.

-   Peri-implant marginal bone loss. Evaluated by radiographic measurements.

-   Histomorphometric assessment of new bone formation, residual allogeneic bone graft and connective tissue.

-   Gain in alveolar ridge width and volumetric reduction of the augmented area. Estimated by clinical or radiographic measurements.

-   Patient-reported outcome measures.

-   Biologic and technical complications.

**Information sources**

The search strategy incorporated examinations of electronic databases, supplemented by a thorough hand-search page by page of relevant journals including "British Journal of Oral and Maxillofacial Surgery", "Clinical Implant Dentistry and Related Research", "Clinical Oral Implants Research", "European Journal of Oral Implantology", "Implant Dentistry", "International Journal of Oral and Maxillofacial Implants", "International Journal of Oral and Maxillofacial Surgery", "International Journal of Periodontics and Restorative Dentistry", "International Journal of Prosthodontics", "Journal of Clinical Periodontology", "Journal of Dental Research", "Journal of Oral Implantology", "Journal of Oral & Maxillofacial Research", "Journal of Periodontology", "Journal of Prosthetic Dentistry", "Journal of Craniofacial Surgery", "Journal of Cranio-Maxillo-Facial Surgery", "Journal of Oral and Maxillofacial Surgery", "Periodontology 2000", "Oral and Maxillofacial Surgery" and "Oral Surgery Oral Medicine Oral Pathology Oral Radiology". The manual search also included the bibliographies of all articles selected for full-text screening as well as previously published reviews relevant for the present systematic review. One reviewer (T.S-J.) performed the search.

**Search strategy**

A MEDLINE (PubMed), Embase, and Cochrane Library search was conducted. Human studies published in English through March 13, 2019 were included. Grey literature, unpublished literature as well as other databases like Scopus, Google Scholar, or Research Gate were not included in the search strategy of the present systematic review. Search strategy was performed in collaboration with a librarian and utilized a combination of Medical subject heading (MeSH) and free text terms. A detailed description of the search strategy is presented in [Appendices 1](#app1){ref-type="app"}, [2](#app2){ref-type="app"}, [3](#app3){ref-type="app"} and [4](#app4){ref-type="app"}.

**Selection of studies**

PRISMA flow diagram presents an overview of the selection process ([Figure 1](#fig1){ref-type="fig"}). Titles of identified reports were initially screened with duplicates removed. Abstracts were assessed when titles indicated that the study was relevant. Full-text analysis was obtained for those with apparent relevance or when the abstract was unavailable. References of papers identified and previously published systematic reviews assessing HARA with allogeneic bone block were cross-checked for unidentified articles. Study selection was performed by one reviewer (T.S-J.).

![PRISMA flow diagram demonstrating the results of systematic literature search. Electronic search resulted in 243 entries. Twenty-four additional articles were identified through hand-searching. Of these 267 articles, 91 were excluded because they had been retrieved in more than one search. A total of 54 abstracts were reviewed and full-text analysis included 28 articles. Thirteen studies were finally included comprising one comparative study and 12 non-comparative studies.](jomr-11-e1-g001){#fig1}

**Inclusion criteria**

Studies assessing implant treatment outcome after HARA with allogeneic bone block compared with autogenous bone block were included by addressing the previously described outcome measures. Review exclusively focused on studies using HARA with block graft and lag-screw fixation prior to implant placement with an observation period after implant loading of at least six months. In addition, at least ten patients should be included and number of implants inserted and surgical procedures had to be clearly specified.

**Exclusion criteria**

Following exclusion criteria were applied: unspecified length of observation period, insufficient description of surgical procedures or inserted implants as well as studies involving medically compromised patients. Likewise, HARA with allogeneic bone graft material in combination with a thermoplastic carrier, simultaneous implant placement, use of tunnel or tent pole techniques or titanium-reinforced membranes as well as studies adding growth factors, bone morphogenetic proteins, fibrin glue or platelet-rich plasma to the grafting material were also excluded. Moreover, letters, editorials, PhD theses, letters to the editor, case reports, abstracts, technical reports, conference proceedings, cadaveric studies, animal or *in vitro* studies and literature review papers were excluded.

**Data extraction**

Data were extracted by one reviewer (T.S-J.) according to a data-collection form ensuring systematic recording of the outcome measures. In addition, relevant characteristics of the study were recorded. Corresponding authors were contacted by e-mail in the absence of important information or ambiguities.

**Data items**

Following items were collected and arranged in following fields: author, patients, pre-operative alveolar ridge width, study design, surgical site, type of grafting material, graft healing period, number of implants inserted, implant healing period, prosthetics, observation period after functional loading, suprastructure and implant survival, implant stability, bone-implant-contact, peri-implant marginal bone loss (PIMBL), histomorphometric measurements, gain in alveolar ridge width, patient-reported outcome measures (PROM), biologic and technical complications.

**Quality and risk of bias assessment**

Quality assessment was undertaken by one review author (T.S-J.) as part of the data extraction process. Cochrane Collaboration's tool for assessing the risk of bias suggested in the Cochrane Handbook for Systematic Reviews of Interventions was used for included randomized controlled trials (version 5.1.0) \[[@B26]\].

Following items were evaluated:

-   Random sequence generation;

-   Allocation concealment;

-   Patient blinding;

-   Outcome blinding;

-   Incomplete outcome data addressed;

-   Selective reporting.

Publications were grouped into the following categories \[[@B27]\]:

-   Low risk of bias (possible bias not seriously affecting results) if all criteria were met;

-   High risk of bias (possible bias seriously weakening reliability of results) if one or more criteria were not met;

-   Unclear risk of bias when too few details were available for classification as high or low risk.

Newcastle-Ottawa scale was applied for non-randomized studies to judge each included study on selection of studies, comparability of cohorts, and the ascertainment of either the exposure or outcome of interest \[[@B28]\]. Stars were awarded with highest quality studies awarded up to nine stars. Included non-randomized studies were categorized:

-   Low-quality (0 - 3 stars);

-   Moderate quality (4 - 6 stars);

-   High quality (7 - 9 stars).

Quality assessment of included non-comparative studies was not conducted, as these studies were assumed to be associated with high risk of bias.

**Statistical analysis**

Parametric data involving PIMBL, gain in alveolar ridge width, volumetric reduction of the augmented area and histomorphometric measurements are presented as mean and standard deviation (M \[SD\]).

RESULTS
=======

**Study selection**

Search results are outlined in [Figure 1](#fig1){ref-type="fig"}. Electronic search resulted in 243 entries. Twenty-four additional articles were identified through hand-searching. Of these 267 articles, 91 were excluded due to being retrieved in more than one search. A total of 54 abstracts were reviewed and full-text analysis included 28 articles. Finally, one comparative \[[@B29]\], and 12 non-comparative studies were included \[[@B30]\].

**Exclusion of studies**

Reasons for excluding 15 studies after full-text assessment were: study could not be excluded before meticulous reading (n = 1) \[[@B42]\], unspecified augmentation procedure (n = 1) \[[@B43]\], unspecified number of implants inserted (n = 1) \[[@B44]\], barrier membrane saturated in platelet-rich plasma (n = 1) \[[@B45]\], immediate implant placement (n = 1) \[[@B46]\], outcome measures could not be identified for HARA in studies involving both horizontal and vertical alveolar ridge augmentation (n = 2) \[[@B47],[@B48]\], observation period after functional loading of six months not fulfilled (n = 3) \[[@B49]\], or observation period not clearly specified (n = 4) \[[@B52]\].

**Study characteristics**

Studies included in the present systematic review consisted of one comparative retrospective radiographic evaluation \[[@B29]\], and 12 non-comparative case-series \[[@B30]\]. Partial and totally edentulous patients with horizontal alveolar ridge deficiencies of the maxilla and mandible were enrolled. The comparative study was performed in accordance with STROBE guidelines and described power calculation of the sample size \[[@B29]\]. Age and gender distribution as well as inclusion criteria and exclusion criteria were specified in all included studies. Alveolar deficiency was defined according to ITI-treatment guide categories \[[@B29]\], Cawood and Howell classification \[[@B33],[@B37]\], Kennedy classification \[[@B41]\], or not specified \[[@B30],[@B34],[@B38]\]. Preoperative width of the alveolar ridge was specified in six non-comparative studies \[[@B31],[@B38],[@B39]\]. No significant difference in patient demographics was reported in the comparative study \[[@B29]\]. The surgical procedure was performed by the same surgeon in two studies \[[@B37],[@B40]\], by two surgeons in two studies \[[@B36],[@B38]\], and by an unknown number in eight studies \[[@B29],[@B39]\]. HARA was performed under local anaesthetics in 10 studies \[[@B29],[@B33],[@B38]\], under general anaesthesia in two studies \[[@B34],[@B37]\], and was not reported in one study \[[@B32]\]. Implant placement was performed under local anaesthesia \[[@B29],[@B33],[@B35],[@B36]\], general anaesthesia \[[@B39]\], or no information was provided about the method used \[[@B32],[@B34],[@B39]\]. FDA bone block was used in the comparative study (Maxgraft^®^ - Botiss Biomaterials GmbH; Zossen, Germany) \[[@B29]\], and two non-comparative studies (ReadiGraft^®^ Canblock - LifeNet Health, Inc.; Virginia Beach, Virginia, USA) \[[@B31],[@B35]\]. DFDA bone block was used in one non-comparative study (OsteoGraft^®^ - Argon Medical Devices Inc; Erlangen, Germany) \[[@B38]\]. FFA bone block from various tissue banks was used in six non-comparative studies including Clinics Hospital Tissue Bank of Universidade Federal do Parana, Curitiba, Brazil \[[@B30]\], Banca dei tessuti della Regione Veneto, Italy \[[@B33]\], Tissue Bank, Careggi Hospital, Florence, Italy \[[@B34]\], Gaetano Pini Orthopaedics Institute, Roma, Italy \[[@B37]\], Tissue Bank, Rio de Janeiro, Brazil \[[@B39]\], UNIOSS, Marilia, Brazil \[[@B40]\]. FDA bone block from Transplant Service Foundation, Sant Boi de LLobregat, Barcelona, Spain was used in one non-comparative study \[[@B36]\]. Origin of the used allogeneic bone block graft was not described in two non-comparative studies \[[@B32],[@B41]\]. Native bone was perforated to ensure vascularization between recipient site and block graft \[[@B29],[@B36]\]. Allogeneic bone block graft was covered by a barrier membrane in eight studies \[[@B29],[@B31],[@B32],[@B35],[@B40],[@B41]\], while no membrane was used in four non-comparative studies \[[@B33],[@B34],[@B38],[@B39]\]. Different implant systems were used including Biohorizons^®^ (BioHorizons Inc; Birmingham, Alabama, USA) \[[@B36]\], BIOMET 3i^®^ (BIOMET 3i LLC; Palm Beach Gardens, Florida, USA) \[[@B29],[@B31]\], blueSKY™ (bredent medical Gmbh & Co.KG, Senden, Germany) \[[@B29]\], MIS implant (Mis Implant Technologies Ltd; Shlomi, Israel) \[[@B38]\], MIS Implant Technologies (Bar Lev Industries; Misgav, Israel) \[[@B31]\], Astra Tech OsseoSpeed^®^ (Dentsply Sirona; Göteborg/Mölndal, Sweden) \[[@B33],[@B37]\], Osseogrip^®^ (Plan 1. Health Srl; Amaro, UD, Italy) \[[@B33]\], PrimaConnex^®^ (Keystone Dental, Inc.; Dallas, Texas, USA) \[[@B34]\], Straumann^®^ (Straumann AG; Basal, Switzerland) \[[@B29],[@B37]\], Systhex^®^ (Systhex Sistema de Implantes Osseointegrados Ltda; Curitiba, Brazil) \[[@B30]\], CM Titamax^®^ Cortical (Neodent; Curitiba, Brazil) \[[@B40]\], and XiVE^®^ (Dentsply Sirona; Göteborg/Mölndal, Sweden) \[[@B37]\]. Implant system used was not specified in three non-comparative studies \[[@B32],[@B35],[@B39]\]. Dropouts were reported in two non-comparative studies \[[@B33],[@B36]\]. None of the included studies provided information about examiner training or calibration.

**Data synthesis**

Meta-analyses were to be conducted only if there were studies of similar comparison, reporting identical outcome measures. However, studies included in the present systematic review revealed considerable variation in patient demographics, allogeneic bone block, barrier membrane, length of observation period, type of suprastructures and implants, dissimilar time frame between implant installation and prosthetic loading as well as different outcome measures. Therefore, a well-defined meta-analysis was not applicable.

**Methodological quality**

Quality of the included comparative study is summarized in [Table 2](#T2){ref-type="table"}.

###### 

Newcastle-Ottawa scale for assessing quality of non-randomized studies \[28\], categorized as low-quality (0 - 3 stars), moderate quality (4 - 6 stars), and high quality (7 - 9 stars)

  ---------------------------------------------------------------------------------------------------------------
  Study                 Year of\      Selection\          Comparability\      Outcome\            Total score/\
                        publication   (maximum 4 stars)   (maximum 2 stars)   (maximum 3 stars)   quality
  --------------------- ------------- ------------------- ------------------- ------------------- ---------------
  Kloss et al. \[29\]   2018          ☆ ★ ★ ★             ★ ★                 ★ ★ ★               8 stars/\
                                                                                                  high quality

  ---------------------------------------------------------------------------------------------------------------

**Outcome measures**

Results of HARA with allogeneic bone block compared with autogenous bone block are presented below and outlined in [Table 3](#T3){ref-type="table"}, followed by results of non-comparative studies in [Table 4](#T4){ref-type="table"}. All reported numerical values are presented as mean values. For each outcome measure, a summary is provided. Survival of suprastructures, implant stability, bone-to-implant contact and PROM were not reported in any of the included studies. Thus, these outcome measures are not described in the following section or outlined in [Table 3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}.

###### 

Horizontal alveolar ridge augmentation with allogeneic bone block graft compared with autogenous bone block graft

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                 Study\           Outcome measures                                                                                                                                                         
                        design                                                                                                                                                                                    
  --------------------- ---------------- ------------------ ----------- --------------------- --------------------- --- ---- --- -------------- --- ----- ----------- --------------------- --------------------- ------
  Kloss et al. \[29\]   Retrospective\   21                 NR          NR                    Mandible\             6   21   6   Single-crown   6   100   5.6 (1.5)   5.2 (1.6)/5.3 (6.2)   5.1 (1.5)/6.3 (6.2)   None
                        study                                                                 ramus: 21                                                                                                           

                                                                                                                                                                                                                  

  21                    FDA: 21          21                 5.5 (1.5)   5.2 (1.4)/4.4 (7.1)   5.2 (1.4)/4.8 (7.2)                                                                                                 
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ARW = alveolar ridge width; BTC = biological and technical complications; FDA = freeze-dried bone allograft; GARW = gain in alveolar ridge width; GH = graft healing time; IH = implant healing time; N = number; NR = not reported; OP = observation period after functional implant loading; PO = postoperative; VRAA = volumetric reduction of the augmented area; SD = standard deviation.

###### 

Horizontal alveolar ridge augmentation with allogeneic bone block graft

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                     Year of\       Study\         Outcome measures                                                                                                                                                                                                                     
                            publication    design                                                                                                                                                                                                                                              
  ------------------------- -------------- -------------- ------------------ ----------- ---------------- ---------- ------------ ----- ------- ------------------------- --------- ------ ------------------------------------------ ---------------------------- -------------- ------------ ---------
  Contar et al. \[30\]      2009           CS             15                 NR          Maxil            FFA: 34    9 (8 - 11)   51    NR      NR                        24 - 35   100    NR                                         NR                           NR             GE: 1        

                                                                                                                                                                                                                                                                                               

  Nissan et al. \[31\]      2011           CS             12                 ≤ 3         Maxil mandible   FDA: 19    6            21    0 - 6   Fixed prosthesis          13 - 60   95.2   No crestal bone loss beyond first thread   NR                           6 months       GE: 4\       
                                                                                                                                                                                                                                                                                  Fistula: 1   

                                                                                                                                                                                                                                                                                               

  5 (SD 0.5)                                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                               

  Nissan et al. \[32\]      2011           CS             24                 ≤ 3         Mandible         FDA: 34    6            85    3       Fixed prosthesis          12 - 66   95.3   NR                                         6 months                     6 months       NR           

                                                                                                                                                                                                                                                                                               

  NBF                       RG             CT             5.6 (SD 1)/5                                                                                                                                                                                                                         

                                                                                                                                                                                                                                                                                               

  40 (SD 28)                29 (SD 24)     27 (SD 21)                                                                                                                                                                                                                                          

                                                                                                                                                                                                                                                                                               

  Orsini et al. \[33\]      2011           CS             10                 1.5 - 2.8   Maxil            FFA: 10    5            14    5       Single crowns             24        100    NR                                         6 months                     5 months       TGL: 1       

                                                                                                                                                                                                                                                                                               

  NBF                       58 (SD 25)     4.6 (SD 0.5)                                                                                                                                                                                                                                        

                                                                                                                                                                                                                                                                                               

  Acocella et al. \[34\]    2012           CS             16                 2 - 4       Maxil            FFA: 18    4 - 9        34    4       Fixed prosthesis          18 - 30   100    NR                                         Non-vital bone: 62 (SD 12)   4 - 9 months   GE: 1        

                                                                                                                                                                                                                                                                                               

  4.1 (SD 0.8)/\                                                                                                                                                                                                                                                                               
  11.5 (0 - 30)                                                                                                                                                                                                                                                                                

                                                                                                                                                                                                                                                                                               

  Nissen et al. \[35\]      2012           CS             40                 ≤ 3         Maxil            FDA: 60    6            83    3       Fixed prosthesis          14 - 82   98.8   NR                                         6 months                     NR             DH: 16       

                                                                                                                                                                                                                                                                                               

  NBF                       RG             CT                                                                                                                                                                                                                                                  

                                                                                                                                                                                                                                                                                               

  33 (SD 18)                26 (SD 17)     41 (SD 2)                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                               

  Novell et al. \[36\]      2012           CS             15                 NR          Maxil mandible   FDA: 36    4 - 6        53    4 - 6   NR                        12 - 60   100    NR                                         NR                           NR             GE: 1\       
                                                                                                                                                                                                                                                                                  FG: 1        

                                                                                                                                                                                                                                                                                               

  Chiapasco et al. \[37\]   2015           CS             19                 ≤ 3         Maxil mandible   FFA: NR    5 - 7        117   5 - 6   NR                        20 - 32   90.2   12 months                                  24 months                    NR             NR           DH: 14\
                                                                                                                                                                                                                                                                                               PGL: 5\
                                                                                                                                                                                                                                                                                               TGL: 2

                                                                                                                                                                                                                                                                                               

  1.6 (SD 1.6)              1.9 (SD 1.4)                                                                                                                                                                                                                                                       

                                                                                                                                                                                                                                                                                               

  Aslan et al. \[38\]       2016           CS             11                 \< 5        Maxil mandible   DFDA: 12   5            32    3       Fixed prosthesis          24        100    NR                                         5 months                     5 months       None         

                                                                                                                                                                                                                                                                                               

  NBF                       RG             CT             1.7 (SD 0.1)/5.4                                                                                                                                                                                                                     

                                                                                                                                                                                                                                                                                               

  40 (SD 25)                40 (SD 21)     19 (SD 15)                                                                                                                                                                                                                                          

                                                                                                                                                                                                                                                                                               

  Deluiz et al. \[39\]      2016           CS             8                  NR          Maxil            FFA: NR    4 - 6        268   4       Fixed prosthesis          12        94     NR                                         NR                           NR             DH: 5\       
                                                                                                                                                                                                                                                                                  PGL: 4\      
                                                                                                                                                                                                                                                                                  TGL: 3       

                                                                                                                                                                                                                                                                                               

  Silva et al. \[40\]       2017           CS             20                 ≤ 6         Mandible         FFA: 50    6            50    6       Single-crown              20 - 42   96     NR                                         6 months                     12 months      GE: 6        

                                                                                                                                                                                                                                                                                               

  NBF                       RG             CT             4 (SD 0.7)/41                                                                                                                                                                                                                        

                                                                                                                                                                                                                                                                                               

  32 (SD 1)                 15 (SD 0)      54 (SD 1)                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                               

  Chaushu et al. \[41\]     2019           CS             14                 NR          Mandible         NR: 24     6            26    3       Mostly fixed prosthesis   12 - 54   100    No crestal bone loss beyond first thread   6 months                     5 (SD 0.5)     GE:6\        
                                                                                                                                                                                                                                                                                  TGL: 2\      
                                                                                                                                                                                                                                                                                  PGL: 6       

                                                                                                                                                                                                                                                                                               

  NBF                       RG             CT                                                                                                                                                                                                                                                  

                                                                                                                                                                                                                                                                                               

  42                        17             41                                                                                                                                                                                                                                                  
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ARW = alveolar ridge width; BTC = biological and technical complications; CS = case series; CT = connective tissue; DFDA = demineralized freeze-dried bone allograft; DH = dehiscence; FDA = freeze-dried bone allograft; FFA = fresh-frozen bone allograft; FG = fracture graft; GAW = gain in alveolar ridge width; GE = graft exposure; GH = graft heling; IH = Implant healing; IS = implant survival; N = number; NBF = new bone formation; NR = not reported; OP = observation period after functional implant loading; PGL = partial graft loss; RG = residual graft; TGL = total graft loss; VRAA = volumetric reduction of the augmented area; SD = standard deviation.

**Survival of implants**

***Comparative studies***

Survival of implants after HARA with allogeneic bone block compared with autogenous bone block from ascending mandibular ramus was 100% for both treatment modalities, after 12 months \[[@B29]\].

***Non-comparative studies***

Survival of implants after HARA with allogeneic bone block varied between 90% and 100%, after 12 to 82 months \[[@B30]\].

***Summary***

The comparative study revealed high short-term implant survival with both treatment modalities. Non-comparative studies disclosed high long-term implant survival after HARA with allogeneic bone block.

**Peri-implant marginal bone loss**

***Non-comparative studies***

PIMBL was 1.2 mm at implant loading increasing to 1.6 and 1.9 mm, one year and two years after implant loading, respectively \[[@B37]\]. No crestal bone loss beyond the first implant thread was reported in two studies, after an observation period between 12 to 60 months \[[@B31],[@B41]\].

***Summary***

PIMBL after HARA with allogeneic bone block was estimated in one non-comparative study demonstrating a PIMBL of 1.9 mm, after two years of implant loading.

**Histomorphometric measurements**

***Non-comparative studies***

Histomorphometric analysis of bone samples after HARA with FDA revealed 33 to 40% new bone formation, 26 to 40% residual graft material and 19 to 41% connective tissue, after six months \[[@B32],[@B35]\]. DFDA showed 40% new bone formation, 40% residual graft material and 19% connective tissue, after five months \[[@B38]\]. FFA disclosed 32 to 58% new bone formation, 15% residual graft material and 54% connective tissue, after six months \[[@B33],[@B40]\]. Non-vital bone volume after HARA with FFA was 62%, after four to nine months \[[@B34]\].

***Summary***

HARA with allogeneic bone block facilitated bone regeneration and new bone formation in non-comparative studies. However, a high percentage of non-vital bone volume was reported after HARA with FFA.

**Gain in alveolar ridge width and volumetric reduction of the augmented area**

***Comparative studies***

Gain in alveolar ridge width was 5.5 mm immediately after HARA with allogeneic bone block and 5.6 mm with autogenous bone block \[[@B29]\]. Corresponding measurements after six and 12 months were 5.2 and 5.2 mm with allogeneic bone block and 5.2 and 5.1 mm with autogenous bone block, respectively. There was no statistically significant difference in gain in alveolar ridge width between the two treatment modalities at any time points \[[@B29]\].

HARA with allogeneic bone block revealed 4.4% and 4.8% volumetric reduction of the augmented area after six and twelve months, respectively \[[@B29]\]. Corresponding measurements for autogenous bone block were 5.3% and 6.3%. There was no statistically significant difference in volumetric reduction of the augmented area between the treatment modalities at any time points \[[@B29]\].

***Non-comparative studies***

Gain in alveolar ridge width was 5 mm after HARA with FDA, after six months \[[@B31]\]. Gain in alveolar ridge width was estimated by subtracting the initial clinical width of the alveolar ridge from clinical width at time of implant placement \[[@B31]\].

Gain in alveolar ridge width was 5.6 mm after HARA with FDA, after six months \[[@B32]\]. Method and location used in estimating gain in alveolar ridge width was not specified. A 5% volumetric reduction of the augmented area was observed, six months after HARA \[[@B32]\].

Gain in alveolar ridge width was 4.6 mm after HARA with FFA, after five months \[[@B33]\]. Gain in alveolar ridge width was measured with computed tomography by subtracting initial width of the alveolar ridge from width at time of implant placement \[[@B33]\].

Immediate gain in alveolar ridge width after HARA with FFA was 4.6 and 4.1 mm, after four to nine months \[[@B34]\]. Gain in alveolar ridge width was measured with calipers by subtracting initial width of the alveolar ridge from width at time of HARA and implant placement. A 11.5% volumetric reduction of the augmented area was observed, four to nine months after HARA \[[@B34]\].

Immediate gain in alveolar ridge width after HARA with FFA was 6.4 mm \[[@B40]\]. Corresponding measurements after six months and twelve months was 4.6 and 4 mm, respectively. Gain in alveolar ridge width was measured on cone beam computed tomography using linear measurements from head of the fixation screw as reference point by subtracting initial width of alveolar ridge from width at time of HARA, implant placement, and twelve months after functional implant loading. A 31% volumetric reduction of the augmented area was observed, after six months, and an additional 10% after twelve months, respectively \[[@B40]\].

***Summary***

The comparative study disclosed no statistically significant difference in gain in alveolar ridge width and volumetric reduction of augmented area between the treatment modalities. Non-comparative short-term studies demonstrated gain in alveolar ridge width of 5 to 5.6 mm after HARA with FDA, and 4.6 mm with FFA. Substantial volumetric stability of the augmented area for implant placement was revealed in most of the non-comparative studies.

**Biologic and technical complications**

***Comparative studies***

No signs of infection, wound dehiscence, graft exposure, or other biologic and technical complications were reported with both treatment modalities \[[@B29]\].

***Non-comparative studies***

No biologic or technical complications were reported in one study \[[@B38]\]. Postoperative pain, oedema, bruising and haematomas have been described after HARA with allogeneic bone block \[[@B30],[@B37],[@B38]\]. Soft tissue dehiscence has been reported in three studies with incidence varying between 27% and 74% \[[@B35]\], while incision line opening occurred in 80% \[[@B41]\]. Graft exposure has been reported in seven studies with incidence varying between 6% and 74% \[[@B30],[@B31],[@B34],[@B36],[@B37],[@B40],[@B41]\]. Partial or total loss of allogeneic bone block caused by infection and/or graft exposure have been reported in four studies \[[@B33],[@B37],[@B39],[@B41]\]. Moreover, soft tissue dehiscence, graft exposure and loss of graft after implant placement and abutment connection was frequently observed in one study \[[@B37]\]. A statistically significant correlation between infection and graft loss was reported in one study \[[@B39]\]. Fracture of the allogeneic bone block was reported in one study \[[@B36]\].

Fistula in the marginal gingiva after crown cementation was described in one patient \[[@B31]\]. The fistula closed spontaneously after curettage in the gingival sulcus \[[@B31]\].

***Summary***

Frequency of short-term and long-term biologic complications including incision line opening, soft tissue dehiscence, graft exposure and partial or total loss of allogeneic bone block was high. Consequently, increased risk of biologic complications may compromise long-term implant survival after HARA with allogeneic bone block.

DISCUSSION
==========

The objective of the present systematic review was to test the hypothesis of no difference in implant treatment outcome after HARA with allogeneic bone block compared with autogenous bone block. One comparative retrospective study with high quality \[[@B29]\], and 12 non-comparative studies \[[@B30]\] fulfilled inclusion criteria. Considerable heterogeneity among included studies prevented meta-analysis performance. Moreover, diversity of evaluation methods, dissimilar observation periods after implant loading and various methodological confounding factors posed serious restrictions to literature review in a quantitative systematic manner. Hence, conclusions drawn from the results of the present systematic review should be interpreted with caution.

Survival of suprastructures and implants are the most important measures for assessment of long-term implant treatment outcomes. However, survival of suprastructure was not reported in any of the included studies. Survival of implant was reported in all included studies, but long-term studies assessing implant survival after HARA with allogeneic bone block compared with autogenous bone block is lacking. Long-term studies assessing HARA with autogenous bone block have demonstrated implant survival of 95.7% and 98.1%, after 10 years \[[@B6],[@B7]\]. A non-comparative long-term study included in the present systematic review disclosed implant survival of 98.8%, after 14 to 82 months \[[@B35]\]. Consequently, long-term randomized controlled trials assessing survival of suprastructures and implants after HARA with allogeneic bone block compared with autogenous bone block are needed before one treatment modality may be considered superior to another.

A newly published systematic review and meta-analysis concluded that HARA maintains peri-implant health over time with low mucosal inflammatory changes and relatively small incidence of PIMBL \[[@B57]\], in accordance with previously published systematic reviews \[[@B58],[@B59]\]. A criterion of successful implant treatment is PIMBL of less than 1 to 1.5 mm during the first year after implant loading and less than 0.2 mm annually, which in turn corresponds to a maximum of 1.7 mm after two years and 3.3 mm after 10 years \[[@B60],[@B61]\]. PIMBL was estimated in one non-comparative study demonstrating 1.6 mm PIMBL, one year after implant loading increasing to 1.9 mm after two years, which is larger than the described implant success criterion \[[@B37]\]. Long-term studies assessing HARA with autogenous bone block have demonstrated limited PIMBL, in accordance with the success criterion \[[@B6],[@B7]\]. A comparative study assessing horizontal and vertical augmentation of extremely atrophic edentulous maxilla's with allogeneic bone block disclosed a statistically significant larger PIMBL with allogeneic bone block compared with autogenous bone block \[[@B47]\]. Allogeneic bone block disclosed 1.5 mm and 1.6 mm PIMBL, one and two years after implant loading, respectively. Corresponding measurements for autogenous bone block was 0.8 mm and 0.9 mm, respectively \[[@B47]\]. Consequently, HARA with allogeneic bone block seems to be associated with higher risk of PIMBL compared with autogenous bone block. However, long-term randomized controlled trials are needed to validate this assumption.

A recent systematic review assessing the efficacy of various grafting materials in alveolar ridge augmentation demonstrated that the degree of bone formation within the grafted volume was 33% with allogeneic bone graft compared with 51% for autogenous bone graft, and 56% for mixtures of autogenous bone graft and other grafting materials \[[@B3]\]. The non-comparative studies revealed 32% to 58% new bone formation after HARA with allogeneic bone block \[[@B32],[@B33],[@B35],[@B38],[@B40]\]. A randomized controlled trial assessing HARA with FFA demonstrated no statistically significant differences in calcified tissue, new bone formation and remaining graft material after four months compared with six months, indicating no beneficial effect of a healing period longer than four months prior to implant placement \[[@B56]\]. Amount of bone regeneration after HARA with allogeneic bone block compared with autogenous bone block has been previously assessed in controlled trials \[[@B19],[@B62]\], and randomized controlled trials \[[@B20]\]. A statistically significant larger amount of vital bone was revealed after HARA with autogenous bone block compared with FFA, after six to eight months \[[@B19]\]. However, histomorphometric analysis of bone samples obtained after HARA with FFA revealed no statistically significant difference in percentage of lamellar bone and new bone formation compared with autogenous bone block, after seven to nine months \[[@B62]\]. Qualitative histologic analysis of biopsies obtained from allogeneic bone block frequently showed areas of non-viable bone, with empty lacunae and poor bone remodelling in the most distant portions from the recipient bed \[[@B62]\]. These results are in accordance with a non-comparative study of the present systematic review disclosing 62% non-vital bone volume after HARA with FFA \[[@B34]\]. Moreover, a randomized controlled trial assessing HARA with FFA compared with autogenous bone block revealed new bone formation with both treatment modalities, but FFA demonstrated clear signs of inflammation \[[@B20]\]. Similar healing patterns have been observed in an experimental study demonstrating statistically significant greater revascularization and bony replacement after HARA with autogenous bone block compared with allogeneic bone block \[[@B63]\]. Autogenous bone block was replaced by newly formed bone, whereas regions of non-vital bone were seen after HARA with allogeneic bone block \[[@B63]\]. Consequently, both treatment modalities seem to facilitate new bone formation. However, amount of bone regeneration after HARA with autogenous bone block seems to be enhanced compared with allogeneic bone block.

HARA with use of a block graft is considered a highly predictable surgical technique for obtaining sufficient bone volume for delayed implant placement \[[@B3],[@B9],[@B10]\]. Gain in alveolar ridge width of more than 4 mm after HARA with autogenous bone block has previously been documented \[[@B4],[@B64],[@B65]\]. The comparative study of the present systematic review revealed equivalent gain in alveolar ridge width and volumetric stability of augmented areas with allogeneic bone block compared with autogenous bone block \[[@B29]\]. Most of the included non-comparative studies revealed similar gain in alveolar ridge width and volumetric stability of the augmented area \[[@B31],[@B38],[@B41]\]. However, continued reduction of the augmented area was reported in one of the included non-comparative studies \[[@B40]\], in accordance with a randomized controlled trial measuring graft resorption at different time points after HARA with allogeneic bone block \[[@B50]\]. Computed tomography and three-dimensional measurements demonstrated mean graft resorption of 13% after four months, 33% after six months, and 51% after eight months, respectively \[[@B50]\]. Moreover, randomized controlled trials using computed tomography and three-dimensional measurements have shown statistically significant larger volumetric reduction of the augmented area after HARA with FFA compared with autogenous bone block \[[@B20],[@B21]\]. In conclusion, HARA with allogeneic bone block seems to gain sufficient alveolar ridge width for delayed implant placement, but an unpredictable volumetric reduction of the augmented area evidently occurs during the healing phase. Studies included in the present systematic review used dissimilar clinical and radiographic two-dimensional linear measurements for assessment of gain in alveolar ridge width and volumetric reduction of the augmented area, which certainly incorporates measurements error. A bone block is an inhomogeneous and three-dimensional anisotropic structure and, therefore three-dimensional methods should be applied for studies assessing volumetric reduction of the augmented area. Therefore, conclusions of the present systematic review may be compromised by use of different measurement techniques and observation periods. Thus, further long-term randomized controlled trails should use standardized methods and three-dimensional volumetric measurements.

Biologic complications including soft tissue dehiscence, graft exposure, partial and total graft loss have been reported in a systematic review after HARA with autogenous bone block \[[@B59]\]. Moreover, temporary and permanent paraesthesia as well as gait disturbances have been described after harvesting autogenous bone graft in conjunction with HARA \[[@B47],[@B62],[@B66]\]. No biologic or technical complications were reported in the comparative study of the present systematic review \[[@B29]\]. However, a previous published study assessing HARA with allogeneic bone block reported dehiscence and graft exposure as well as partial and total loss of graft before and after implant placement compared with no complications after HARA with autogenous bone block \[[@B62]\]. Likewise, graft exposure and loss have been described after HARA with allogeneic bone block compared with no biologic complications with autogenous bone block \[[@B67]\]. High incidence of biologic complications including incision line opening, soft tissue dehiscence, graft exposure, partial or total loss of the allogeneic bone block were reported in some included non-comparative studies \[[@B31],[@B37],[@B39]\] of the present systematic review. Similar observations have been described after HARA with allogeneic bone block \[[@B45],[@B48],[@B49]\]. Moreover, a comparative study assessing horizontal and vertical augmentation of extremely atrophic edentulous maxilla's with allogeneic bone block graft disclosed increased soft tissue dehiscence, graft exposure and sequestration before and after implant placement with allogeneic bone block compared with autogenous bone block from the iliac crest \[[@B47]\]. Hence, HARA with allogeneic bone block seems to be associated with increased risk of biologic complications at the recipient site, which may compromise long-term implant survival.

Allogeneic bone block use for HARA compared with harvesting autogenous bone block is associated with obvious advantages for patients. Consequently, comparison of the two treatment modalities should contain evaluation of donor site morbidity, inflammatory reactions, economic perspective, PROM and length of patient treatment time. However, these aspects have not been addressed in any of the included studies.

CONCLUSIONS
===========

The hypothesis of no difference in implant treatment outcome after horizontal alveolar ridge augmentation with allogeneic bone block compared with autogenous bone block could neither be confirmed nor rejected due to insufficient available knowledge. A comparative retrospective short-term study revealed no statistically significant difference in implant treatment outcome between the two treatment modalities. Non-comparative long-term studies demonstrated high implant survival, gain in alveolar ridge width and bone regeneration after horizontal alveolar ridge augmentation with allogeneic bone block. However, high incidence of biologic complications including soft tissue dehiscence, exposure of allogeneic bone block, partial or total loss of the block graft were reported in non-comparative studies. Moreover, dissimilar evaluation methods, observation periods, outcome measures and various methodological confounding factors posed serious restrictions for literature review in a quantitative systematic manner. Hence, conclusions drawn from results of this systematic review should be interpreted with caution and further long-term randomized controlled trials including assessment of donor site morbidity, patient-reported outcome measures, economic perspective and patient treatment time are needed before definite conclusions can be provided about horizontal alveolar ridge augmentation with allogeneic bone block compared with autogenous bone block.
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